

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Toshio DOI et al.	)	Group Art Unit:
	)	
Application No.: 10/571,511	)	Examiner: Not Yet Assigned
	)	
Filed: 3/10/2006	)	
	)	
For: METHOD AND KIT FOR	)	Confirmation No.: 8941
DETECTING PROLIFERATIVE	)	
DISEASES CAUSING	)	
SCLEROSIS, PREVENTIVE	)	
AND/OR REMEDY FOR	)	
PROLIFERATIVE DISEASES	)	
CAUSING SCLEROSIS AND	)	
METHOD AND KIT FOR	)	
IDENTIFYING SUBSTANCE	)	
EFFICACIOUS IN PREVENTING	)	
AND/OR TREATING	)	
PROLIFERATIVE DISEASES	)	
CAUSING SCLEROSIS	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.**  
**§ 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.  
Copies of the U.S. patent publications are not enclosed. Each document listed on the

attached IDS PTO-SB-08 was cited in a communication in a counterpart Patent Cooperation Treaty application, and this Information Disclosure Statement is being filed before the first action on the merits of this application.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: 11/29/06

By: 

Chris T. Mizumoto  
Reg. No. 42,899

IDS Form PTO/SB/08: Substitute for form 1449A/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<i>Application Number</i>	10/571,511	
			<i>Filing Date</i>	3/10/2006	
			<i>First Named Inventor</i>	Toshio DOI et al.	
			<i>Art Unit</i>		
			<i>Examiner Name</i>	Not Yet Assigned	
Sheet	1	of	1	<i>Attorney Docket Number</i>	10084-0004.00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-			
	AB	US-			
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	BA	WO 03/042211 A1	05-22-2003	Smithkline Beecham corp.		
	BB					
	BC					
	BD					

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
	CJ	Written Opinion of the International Searching Authority for PCT/JP2004/013124 mailed June 29, 2006	
	CG	OH, S. Paul, Activin receptor-like kinase 1 modulates transforming growth factor- $\beta$ 1 signaling in the regulation of angiogenesis, PNAS, March 14, 2000, 1626-2631, vol. 97, no. 6	
	CH	GUPTA et al., BMP-2/ALK3 and HGF signal in parallel to regulate renal collecting duct morphogenesis, J. Cell Sci. (2000 Jan), Vol. 113, Pt 2, pp. 269-278	
	CE		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.